| (+)-LRH-1 agonist-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (+)-Bornyl acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| (-)-Syringaresinol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| (14S,15R)-14-Deoxyoxacyclododecindione |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Salicylate choline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (20R)-Protopanaxadiol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| (2S)-OMPT |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (2S)-OMPT triethylamine, in ethanol:chloroform (1:1), 98% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| (5R)-5-Hydroxytriptolide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| (5Z,2E)-CU-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.03% |
| (6R,7R)-Epoxy-1-oleanen-3-ol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (E/Z)-3-Hydroxylicochalcone A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (E/Z)-Necrosulfonamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.03% |
| (E/Z)-OSM-SMI-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (R)-IL-17 modulator 4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.56% |
| (R)-TCB2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (R)-Zelebrudomide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.93% |
| (R,R)-VVD-118313 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| (rac)-Poriol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (Rac)-Z-FA-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (S)-Elobixibat |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (S,S)-Formoterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (±)-10-Gingerol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (±)-Lisofylline-d4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (±)-Lisofylline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.57% |
| (±)-Praeruptorin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| (±)17(18)-EpETE-ethanolamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| (±)19(20)-EDP ethanolamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1,1′-Ethylidenebis[L-tryptophan] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.04% |
| 1,11b-Dihydro-11b-hydroxymedicarpin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tetramethyluric acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| 1,4-Dihydroxy-2-naphthoic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| 1,4-Dihydroxy-2-naphthoic acid (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| 1-Linoleoyl Glycerol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| 1-Linoleoyl Glycerol-d5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1-Oleoyl-2-hydroxy-sn-glycero-3-phospho-L-serine sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| 1-Prenyl-2-methoxy-6-formyl-8-hydroxy-9H-carbazole |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 10(11)-Cl-BBQ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| [10]-Shogaol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| [10]-Shogaol (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 10-Gingerol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.48% |
| 10-Hydroxy-2-decenoic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| 10-Hydroxydecanoic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| 12-Dehydrogingerdione |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 12-Nitrolinoleate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 12-Oxo phytodienoic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 12-Oxo phytodienoic acid (≥90%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
92.2% |
| 13-Methylberberine chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.16% |
| 15-LOX-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 19-epi-Scholaricine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.14% |
| 1beta-Hydroxyalantolactone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| 1α-Hydroxyvitamin D5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2'-Fucosyllactose |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| 2-ARA-LysoPtdEtn |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2-Hydroxy Imiquimod |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2-O-Methylatromentin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2-Undecanone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| 2-Methacryloyloxyethyl phosphorylcholine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| 23ME-00610 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 3′,4′,7-Trihydroxyflavone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.04% |
| 3-Feruloylquinic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.49% |
| 3-O-Methyldopa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.55% |
| 3-O-Methyldopa-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| 3-O-Methyldopa-d3 hydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 3-Acetyldeoxynivalenol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.38% |
| 3-Acetyldeoxynivalenol-13C17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| 3-Methylcarbazole |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.78% |
| 36R-D481 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| 4'-Acetoxy resveratrol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 4′-Hydroxywogonin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.22% |
| 4,5-Dehydro-6-oxoallosecurinine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 4,7-Dimethoxy-5-methyl-1,3-benzodioxole |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 4-DAMP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| 4-Ethoxybenzaldehyde |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 4-Methoxycinnamic acid ethyl ester |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.72% |
| 4-Methoxylonchocarpin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| 4-Allylcatechol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.60% |
| 4L2-P13D |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 5(S)15(S)-DiHETE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| 5-Androstenetriol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 5-Hydroxy-6,7-dimethoxyflavone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 5-LOX-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 5-Methoxy-DL-tryptophan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.32% |
| 5-Methoxytryptophol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Leucrose |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.53% |
| 6-Methoxymellein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 6-Demethoxytangeretin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.37% |
| Oxidopamine hydrobromide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.42% |
| Oxidopamine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.97% |
| 7-O-Galloyl-D-sedoheptulose |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 7-O-Methyl glabranin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 7ß-Hydroxycholesterol-d7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.73% |
| 7β-Hydroxycholesterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| 8-(6,7-Dihydroxy-3,7-dimethyl-2E-octenyloxy)psoralen |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 8-Hydroxyguanosine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.48% |
| A-9758 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| a15:0-i15:0 PE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Abacavir hydroxyacetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| Abacavir hydroxyacetate (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Abdakibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.30% |
| ABM-125 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.92% |
| ABT-147 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ABT-325 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.75% |
| ABT-546 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ABX-IL8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.70% |
| ABX196 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-Pro-Gly-Pro-OH |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| Ac-YVAD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.99% |
| Ac-YVAD-CHO acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acetyl hexapeptide-49 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.58% |
| Acetyl zingerone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| AChE-IN-85 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acloproxalap |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Acutissimalignan B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AD-35 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Adakitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| ADAM17-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Adenosine receptor antagonist 6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ADP-β-S trilithium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
94.9% |
| ADP-β-S trisodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ADR58 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Adrenocorticotropic hormone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| Adrenocorticotropic hormone TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| ADS032 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| AF12198 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| AGN 225660 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGN-190121 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AHL-7160 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AHR agonist 10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AIM4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.07% |
| AK114 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Akt/NF-κB/MAPK-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Alcudacigib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Alcudacigib TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.13% |
| Alendronate sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Alendronic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Alisol A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.59% |
| Alisol A (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Altrakincept |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ALV1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.62% |
| AM9053 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.36% |
| AM9928 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AMG-108 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| AMG-317 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amilo-5MER |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amilo-5MER TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| Amizon |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Ammonium glycyrrhizinate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.68% |
| AMY109 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AN-2898 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AN-3485 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.38% |
| AN-3485 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ANB004 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ANB032 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anemoside A3-methyl 6-aminohexanoate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.62% |
| Anflekitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Angoline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| Anhydro-Ouabain |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-CD160 Antibody (MAT 302) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-CD19 Antibody (4G7) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| Anti-CD1a Antibody (OKT-6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-CD25/IL-2Rα Antibody (7G7B6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Human IL-6 Antibody (FM101) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Human/Mouse GRP78 Antibody (N88) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-10 Antibody (JES3-19F1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-10RB Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-10Rα Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-11 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-12 p70 Antibody (20C2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Anti-IL-12RB2 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-12Rβ1 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-13 Antibody (C836) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.20% |
| Anti-IL-13 Antibody (CNTO 607) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-15 Antibody (DISC0280) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.35% |
| Anti-IL-17F Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-17RB Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-18 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-18RAP Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-18Rα Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-19 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-1R Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-1RA Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-21R Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-23R Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-24 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-25 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| Anti-IL-26 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-27RA Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-2R gamma Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-31 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-32 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-34 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.01% |
| Anti-IL-4 Antibody (MP4-25D2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥95.0% |
| Anti-IL-5 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-6 Antibody (Chugai SK2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-9 Antibody (MH9A4) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL11 Antibody (X203) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.53% |
| Anti-IL11 Antibody (X203, Mouse IgG) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.45% |
| Anti-IL11RA Antibody (Hu16E12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL11RA Antibody (X209) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.75% |
| Anti-IL25/IL17E Antibody (ABM109.2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL6 Antibody (MH166) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 102 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 107 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 109 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 111 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 112 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 115 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 116 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 117 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 118 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 35 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Anti-inflammatory agent 41 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 42 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Anti-inflammatory agent 54 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 55 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 58 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 59 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 62 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 64 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 74 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 76 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 77 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 89 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 90 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 91 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 95 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 99 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-iNKT Cell Antibody (6B11) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-LIF Antibody (MSC-1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.51% |
| Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95% |
| Anti-Mouse CD132 (common γ chain) Antibody (3E12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse CD25 Antibody (7D4) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Anti-Mouse CD25/IL-2Rα Antibody (PC-61.5.3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99% |
| Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse Galectin-9 Antibody (RG9-1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.64% |
| Anti-Mouse GITR Antibody (DTA-1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.47% |
| Anti-Mouse IL-10 Antibody (JES5-2A5) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.666% |
| Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.08% |
| Anti-Mouse IL-12 Antibody (R1-5D9) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥95.0% |
| Anti-Mouse IL-12 p35 Antibody (C18.2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95% |
| Anti-Mouse IL-12 p40 Antibody (C17.8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.691% |
| Anti-Mouse IL-12 p75 Antibody (R2-9A5) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse IL-15 Antibody (AIO.3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥95.0% |
| Anti-Mouse IL-17A Antibody (BZN035) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.90% |
| Anti-Mouse IL-17F Antibody (MM17F8F5.1A9) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥95.0% |
| Anti-Mouse IL-18 Antibody (YIGIF74-1G7) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.12% |
| Anti-Mouse IL-1a Antibody (ALF-161) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥95.0% |
| Anti-Mouse IL-1b Antibody (B122) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99% |
| Anti-Mouse IL-1R Antibody (JAMA-147) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Anti-Mouse IL-2 Antibody (JES6-1A12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99% |
| Anti-Mouse IL-2 Antibody (JES6-5H4) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.62% |
| Anti-Mouse IL-2 Antibody (S4B6-1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.97% |
| Anti-Mouse IL-21R Antibody (4A9) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Anti-Mouse IL-23 p19 Antibody (G23-8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.14% |
| Anti-Mouse IL-25 Antibody (2C3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Anti-Mouse IL-27 p28 Antibody (MM27.7B1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Anti-Mouse IL-3 Antibody (MP2-8F8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Anti-Mouse IL-4 Antibody (11B.11) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse IL-4 Antibody (11B11) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.67% |
| Anti-Mouse IL-4 Antibody (BVD6-24G2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.486% |
| Anti-Mouse IL-4Rα Antibody (REGN1103) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Anti-Mouse IL-6 Antibody (MP5-20F3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| Anti-Mouse IL-6R Antibody (15A7) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Anti-Mouse IL-7Rα/CD127 Antibody (A7R34) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Anti-Mouse IL-9 Antibody (9C1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Anti-Mouse Jagged 2 Antibody (HMJ2-1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse NKp46 Antibody (29A1.4) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse TSLP Antibody (28F12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.395% |
| Anti-Mouse/Human IL-5 Antibody (TRFK5) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.80% |
| Anti-Mouse/Human IL-7 Antibody (M25) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.43% |
| Anti-Mouse/Rat IL-17A Antibody (17F3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| Anti-MRSA agent 44 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-neuroinflammation agent 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Rat CD25 Antibody (OX-39) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Rat IL-4 Antibody (OX-81) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Anti-TSLP Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antiallergic agent-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antibiofilm agent-20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antibiofilm agent-21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antiflammin-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antifungal agent 136 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.15% |
| Antileishmanial agent-44 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antioxidant agent-22 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antitumor agent-173 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| APG808 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| APH02174 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| APH02174 hemiformic |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Apoptosis inducer 42 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| APX-007 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| APX002 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| APY0201 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.42% |
| Arabinoxylan (Medium viscosity) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95% |
| Aristolochic acid D |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Aritinercept |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| ARN14494 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.08% |
| Arnicolide B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Arucadiol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Arvelexin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AS1940477 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AS2677131 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AS2795440 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ascorbyl tetra-2-hexyldecanoate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| ASK1-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| Asperflavin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Astragaloside II |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.45% |
| Atinvicitinib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.62% |
| Atiprimod dimaleate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ATP disodium salt, 100 mM Solution, PCR Grade |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ATR-107 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Avenanthramide C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.13% |
| AVP-13358 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AX-024 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| AX-024 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| AX-024 hydrochloride (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AZ3246 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.92% |
| AZD4144 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| β-Bisabolol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BAA473 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.93% |
| BAL-0028 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Balekafusp alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.37% |
| BC-1471 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| BC12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BC12-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BChE-IN-44 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BChE-IN-49 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BChE/MAO-B-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BChE/p38-α MAPK-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BD-AcAc2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Bemarituzumab (FUT8-KO) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| Bempikibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.00% |
| Bengamide B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Benralizumab (anti-IL5RA ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| Benzo-17R-RvD2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Benzylurea |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| BER-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Berkeleyacetal C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Betamethasone succinate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Betinukibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Bexatamig |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.06% |
| BI-765423 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.52% |
| Bifikafusp alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96% |
| BIHC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
| Biotin-labeled ISD sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BIRT 377 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Bizaxofusp |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BL-9020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.32% |
| BLT1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BML-280 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| BMP-4 (15-24) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BMP-4 (15-24) acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| BMS-195614 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.5% |
| BMS-279700 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BMS-981164 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.36% |
| BMS-986010 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BMS-986126 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BMS-986251 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BMS-986331 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BMS-986408 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.35% |
| BODIPY-phenyl-amide-alkyne |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Bosakitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| BP79 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BPN-37440 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Brazilein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| BRD4 Inhibitor-38 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BRD4-BD1/2-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| BRD6989 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.54% |
| Broussoflavonol G |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Broussonin E |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.11% |
| BSF2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BT-063 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| BuChE-IN-20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BuChE-IN-23 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Burfiralimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.20% |
| Butrin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Butyrolactone Ia |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| c-(2'FdAMP-2'FdIMP) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| C6 D-Threo Ceramide (d18:1/6:0) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| C6 L-threo Ceramide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAII-IN-15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Calamenene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Calenduloside E |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.07% |
| Calonysterone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Camidanlumab tesirine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.52% |
| Camoteskimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.56% |
| Camtarkibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| CAN10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.04% |
| Cannabitwinol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cappariloside A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cardiolipin (16:1/16:1/16:1/16:1) sodium salt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Casdozokitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.49% |
| Casein hydrolysate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAT-2200 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cathelicidin-PY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cathepsin L-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAY10512 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.0% |
| CAY10594 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.64% |
| Cbl-b-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| Cbl-b-IN-28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cbl-b-IN-29 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cbl-b-IN-30 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cbl-b-IN-33 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CBS-3408 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CBT-295 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| CC-90002 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.97% |
| CD-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CD28-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CD28-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CDK6/9-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CDN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CDP-484 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| Cefonicid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cefonicid monosodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CEP-37248 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cer (t18:0/26:0) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ceramide 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Ceramide 3-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| CF-Carvacrol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CF-Vanillin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chamissonolide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chloranthalactone B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CHNQD-03005 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chuanbeinone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chymostatin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| CIAC101 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CIDD-8633 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| cis-Mulberroside A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Citrullinated LL-37 1cit |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Citrullinated LL-37 2cit |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CJ-14897 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CJM-112 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.65% |
| CK-102 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CK-119 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CK-17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CKD-712 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Clerodendrin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| CLP-d2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cm-CATH2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CMD178 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CMD178 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| CN016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CNTO-5825 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.18% |
| CNTO-6785 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CNTO4088 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Coelonin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Colchicine derivative-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| COM503 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Comekibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.43% |
| Convulxin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cot-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| COVA322 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| COX-2-IN-60 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| COX-2-IN-63 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| COX-2-IN-66 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| COX-2/5-LOX-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| COX-2/CaV2.2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| COX-2/HDAC6-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CPL302-253 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Crebankitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| Crusekitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.949% |
| CSF1R-IN-27 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CSL-360 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CT-133 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CTX-471 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.00% |
| CU-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CX-659S |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cyanidin 3,5-diglucoside chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| Cyanidin 3,5-diglucoside chloride (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cyanidin-3-O-arabinoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.71% |
| Cyclo(L-Ile-D-Leu) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| cyclo-Cannabigerol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cynandione A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.6% |
| Cytogenin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cytokine-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cytoxazone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D(+)-Raffinose pentahydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| d-(RYTVELA) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Di-O-methyldemethoxycurcumin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.64% |
| d-T101 peptide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D-α-Tocopherol acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.32% |
| D-Mannuronic acid sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| DA-E 5090 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dactyllactone A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Darutoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Dazcapistat |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Dazupegleukin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DB-310 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DC-Chol hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| DC-PGKI |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DC-Y13-27 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| DCLK1-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Decarine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dectrekumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Defensin HNP-1 human TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.08% |
| DEL-C1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deltamethrin-d6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Denotivir |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dersalazine sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deucravacitinib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Deucravacitinib hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deucravacitinib-13C,d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dexamethasone phosphate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.89% |
| Dexamethasone phosphate-d4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DF6002 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DGKα&ζ-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DGKα-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DGKζ-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DGKζ-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Diacetoxy-6-gingerdiol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Dichotomine C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Diethanolamine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.17% |
| Diethanolamine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Diethylcarbamazine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Digitoxigenin-3-O-β-D-quinovoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dihydrobonducellin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dimethyl diacetyl cystinate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Diphenylcyclopropenone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Divaricatol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DLX-105 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DLX2323 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Docosahexaenoyl serotonin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| Donzakimig |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.67% |
| DOTA-Pep-1L |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DOTA-Pep-1L TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.60% |
| DpC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.73% |
| DPO-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.39% |
| DPP-1-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DPP-4-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DPP4-In hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DRAK1/2-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Drotokibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.05% |
| DT-5461 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dual Cathepsin L/JAK-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.47% |
| E5090 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EC330 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.29% |
| Ecleralimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.35% |
| eeAChE-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Efarindodekin alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Efbalropendekin alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.17% |
| Efdelikofusp alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Efercoleukin alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Efineptakin alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| Efmarodocokin alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Efpixileukin alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Eftezirleukin alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Efzilonkofusp alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-144 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-200 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-206 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR/Cytokine-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGR-1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.07% |
| EGR-1-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.13% |
| Eicosapentaenoyl serotonin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| Elaidic acid-d17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Elaidic acid-d9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| Elsilimomab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.44% |
| Elubrixin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Elubrixin hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Elubrixin tosylate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.14% |
| EMD638683 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Emfizatamab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.495% |
| ENDO12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Endothelin 1 (swine, human), Alexa Fluor 488-labeled |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Endotoxin inhibitor |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Endotoxin inhibitor TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Envudeucitinibum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.56% |
| ENx-108A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EP4 receptor antagonist 7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| EP4 receptor antagonist 8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ephemeranthol A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Episappanol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.80% |
| Eps8 peptide 327 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ER-464195-01 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| Erepdekinra |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.63% |
| Etazolate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ETC-501 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.40% |
| ETI41 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ETI60 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| Eupalestin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exemestane-19-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| F 991 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| F8-IL-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FABP4/5-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FASN/SCD-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FB-825 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FB704A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Felcorekibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.637% |
| FHND5032 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| FIP22 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.53% |
| FITC-labeled ODN 2216 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
93.96% |
| FK3453 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FKK6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.14% |
| Flagellin from S. typhimurium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95% |
| Flizasertib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Flt-3L-Ig (hum/hum) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| FM-202 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FM-303 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Forsythoside I |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| FPR2 agonist 5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FSVVPSPK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FuBIG |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| G721-0377 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GABAAR/5-HT2AR modulator-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Galvokimig |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.74% |
| Gamma-glutamylcysteine ammonium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ganglioside GQ1b (bovine) sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| Ganglioside GT1b (bovine) trisodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ganoderic acid K |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GAP214 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GB-0895 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.67% |
| GCS-11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GCS-12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GDC-2394 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| GDC-2394 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GE1111 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.73% |
| GED 0507-34-Levo |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Geranial |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| Geranylgeranyl pyrophosphate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Geranylgeranyl pyrophosphate triammonium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| GFH018 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.59% |
| GFH018 methylbenzenesulfonate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GI-Y2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GIBH-130 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| Gimvekibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.50% |
| Ginsenoside F3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Ginsenoside Rg4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Girolline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GlcNAc-MurNAc |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.37% |
| GLPG4970 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| Glucocorticoid receptor/IL-6-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Glucocorticoid receptor/IL-6-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gluconate-13C6 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Glutathione trisulfide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Glycolipid C34 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Glycoursodeoxycholic acid 3-sulfate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GNE-6893 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Goflikicept |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.32% |
| Gomisin N |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| GP130 modulator-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.29% |
| GP130 modulator-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.15% |
| GP130 receptor agonist-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| GP130-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GPR68 antagonist 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GSK-1070806 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| GSK-1482160 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.67% |
| GSK-2330811 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.69% |
| GSK-315234 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.16% |
| GSK-679586 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GSK1370319A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GSK1995057 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.09% |
| GSK2618960 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.66% |
| GSK699 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.80% |
| GSK702 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GSK789 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GSTO1-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GSTO1-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gumokimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.95% |
| GV-001 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GW-405833 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.91% |
| GW405833 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.59% |
| GYY4137 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.64% |
| GYY4137 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GYY4137 (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HAIL-12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Haplopine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| HB-0017 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HB-107 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hck-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC3 degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC3 degrader-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC6 degrader-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.55% |
| HDAC6-IN-80 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hecubine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hedycoronen A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HEI3090 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| HEP-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Heparin disaccharide I-H trisodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Heparin disaccharide II-S trisodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Heparin disaccharide III-S trisodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hericene A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.84% |
| Hibiscetin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HJC0123 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.06% |
| hMAO-B-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HMGB1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.40% |
| HMGB1-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| House Dust Mite Extract, from D.pteronyssinus |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPK1-IN-43 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPK1-IN-56 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPK1-IN-57 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPK1-IN-58 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPK1-IN-64 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPK1-IN-65 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPK1-IN-68 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPK1-IN-69 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPN601 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HS-276 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.93% |
| HS-276 formic |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HS-276 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hs02 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HSP90-IN-31 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HSP90α-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| hSTING activator-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HTS07944 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Humanized anti-tac (HAT) binding peptide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HuMax-IL15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HVF18-a3-d |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hydrangenol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| Hydrocortisone hemisuccinate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hydrocortisone hemisuccinate hydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.42% |
| Hydrocotarnine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| Hydrostatin-TL1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HZD37-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IAV-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IBI-325 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IBI-363 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| IC 100 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Icotrokinra |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Icotrokinra acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Icotrokinra hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| IDO1-IN-27 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IDO1-IN-34 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IDO1/TDO-IN-12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| iE-DAP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| iE-DAP dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IIIM-1266 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IIIM-1270 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.78% |
| IIIM1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IKK 16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| IKK 16 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| IKZF2-degrader 5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-15-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| IL-17 modulator 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17 modulator 1 disodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.38% |
| IL-17 modulator 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17 modulator 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| IL-17 modulator 4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.19% |
| IL-17 modulator 4 sulfate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17 modulator 5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17 modulator 6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17 modulator 8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17 modulator 9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17A antagonist 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| IL-17A antagonist 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.25% |
| IL-17A inhibitor 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| IL-17A inhibitor 4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17A modulator-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.80% |
| IL-17A modulator-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.44% |
| IL-17A modulator-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.37% |
| IL-17A-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-1β-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.45% |
| IL-1β-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.38% |
| IL-1β-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-1β-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| IL-23 cyclic peptide inhibitor 105 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-23 cyclic peptide inhibitor 281 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-23R inhibitor peptide-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| IL-4-inhibitor-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.04% |
| IL-6 aptamer sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.85% |
| IL-6 aptamer sodium scrambled negative control |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-6-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-6-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| IL-6-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-6/RIPK3-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL10 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Il10 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Il10 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL13Rα2 D1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.17% |
| IL15 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Il15 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Il15 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL17A Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Il17a Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Il17a Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL17A-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL1A Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL1B Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL2 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Il2 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Il2 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL23A Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Il23a Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Il23a Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL4 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Il4 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Il4 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL4I1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| IL4RPep-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL4RPep-1 acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.61% |
| IL5 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Il5 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Il5 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL6 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Il6 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Il6 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ilekudinol B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IMA-026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IMG-008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Iminostilbene-d10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IMM20324 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Immuno modulator-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Imneskibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| Imsidolimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.63% |
| Inbakicept |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.94% |
| INCB191358 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Inclisiran sodium scrambled negative control |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| INF 195 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.58% |
| iNOs-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.07% |
| iNOs-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Inosine pranobex |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.59% |
| Interleukin II (60-70) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Interleukin-6 fragment (human) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IRBP(651-670) human, mouse |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.13% |
| IRBP(651-670) human, mouse TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IRF1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| IRF1-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| IRF5-CPP5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| ISD sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.02% |
| Isoeucommin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Isomucronulatol 7-O-glucoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| Isopongaflavone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Isoprothiolane-d4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Isoquinoline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.28% |
| Isostearic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.0% |
| Isostrictiniin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ISP-VT |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| iST2-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.58% |
| Itaconic acid prodrug-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Itepekimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.496% |
| IX 207-887 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.96% |
| JAK1-IN-20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| JAK1/2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.36% |
| JAK2/STAT3-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| JAK2/STAT3-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| JH-FK-08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| JNJ627 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| JNK2/MKK7 PPI-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| JS007 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| JTE-151 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| JTE-607 free base |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| JTE-907 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.54% |
| JWX-A0108 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| K-832 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| K284-6111 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Kaempferol 3-O-(2G-glucosylrutinoside)-7-O-glucoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Kaempferol 3-O-β-D-glucuronide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.47% |
| KB-0118 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KBD4466 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Keap1-Nrf2-IN-25 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Keap1/Nrf2/ARE activator 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KHK2823 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KHK2840 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KMS99220 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.48% |
| Koaburaside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KOR agonist 7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KPLH1130 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| KRN7000 analog 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KRN7000 analog 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KRN7000 analog 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KSI-028 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Kylo-0603 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KZR-8445 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KZR-8445 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| γ-Glutamylvaline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Lauroyl-L-carnitine chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Lauroyl-L-carnitine-d3 chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Lauroyl-L-carnitine-d9 chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| L6H21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.19% |
| Larnefpendekin alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.16% |
| LAS190792 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lasrekibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.056% |
| LC-04-045 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.56% |
| LC-PDA-01 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LCC-12 formate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Lck Inhibitor III |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lck-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LD03-DEX |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LDDN-0003499 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LEAP-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.75% |
| Lecomkafusp alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lemairamin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LF 1695 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LG190155 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lib2-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| Ligusticum cycloprolactam |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Linderaspirone A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LIQ1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.40% |
| Lithocholic amide-C2-N(didecane) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lixarkitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99% |
| LM-021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.27% |
| LMP-420 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LMT-28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.75% |
| Lobeglitazone sulfate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| Logmalicid B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LPZ-51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LRH-1 agonist-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.58% |
| LT-1339-553 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lunlekitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Lunsekimig |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| Luteolin-4'-O-glucoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| LY2189102 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LY3509754 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.35% |
| Lyn peptide inhibitor |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.35% |
| Lyn peptide inhibitor TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lys-D-Pro-Thr |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| Lysophosphatidylcholine C19:0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| LZ-07 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.27% |
| M04 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M199 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.55% |
| M351-0056 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.48% |
| M464 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.58% |
| M802 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Madindoline A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Madindoline B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Malvidin-3-glucoside chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Malvidin-3-glucoside chloride (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Manfidokimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| MAO-A-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MAPK-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maresin 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.2% |
| MAS825 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.83% |
| Maxadilan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MBL-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MC-100093 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MC4762 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MDL-811 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| MEDI-7836 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MEDI-9314 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Meloside A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.72% |
| Melredableukin alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.22% |
| Melrilimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.07% |
| MeOSuc-AAPV-CMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.01% |
| Mepolizumab (anti-IL5) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.50% |
| Mergetpa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.55% |
| Mesopram |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.80% |
| Metamizole hemimagnesium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mik-Beta-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Militarine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Mincle agonist 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mipletamig |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99% |
| Mizoribine prodrug-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mizoribine prodrug-2 trifluoroacetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MK-1966 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.17% |
| MK169 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MK175 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ML345 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.37% |
| MM-102 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.09% |
| MNP2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Momordicine I |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.0% |
| Monoolein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Monotropein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| MOR-106 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.42% |
| Morcamilast |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.92% |
| MR2938 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MSP-1 P2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MT-2990 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MT204 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Multi-target kinase-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Multitarget AD-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Murrayafoline A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| MW11-h317 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Myelopeptide-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| N-Acetyl-D-glucosamine-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| N-Acetyl-L-tryptophan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| N-Acetyl-L-tryptophan-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| N-Palmitoyl-D-glucosamine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| N-Acetyl-D-glucosamine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.20% |
| Naamidine J |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| nAChR antagonist 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nadifloxacin-d5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nangibotide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.53% |
| Nangibotide TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| Naphazoline-d4 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nastorazepide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Nastorazepide hemicalcium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Navepdekinra |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.58% |
| NDI-101150 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Necrosulfonamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.61% |
| NecroX-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| NEK7 degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| NEK7 degrader-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NEK7 degrader-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NEK7-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nemvaleukin alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.50% |
| Neral |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.87% |
| Neuroprotective agent 16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NF-κB-IN-20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NF340 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NFAT Transcription Factor Regulator-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.98% |
| NFAT-133 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NI-1201 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NIK-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nitroparacetamol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nivocasan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NK7-902 diTFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| NLRP3 modulator 7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-24 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-25 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.78% |
| NLRP3-IN-42 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-54 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-58 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-69 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-71 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-72 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-75 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-76 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-77 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-79 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.10% |
| NLRP3-IN-81 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-83 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-84 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-85 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-86 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-87 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-88 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-89 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-91 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3/URAT1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NN-8828 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.89% |
| NO-prednisolone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.58% |
| NOD1-RIPK2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NOD2 agonist 4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NOD2 antagonist 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.57% |
| Nodosin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.61% |
| Nogapendekin alfa (his tag) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.62% |
| Nolavetbart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96% |
| Nomelcitinib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nonadecanoic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Nonoxynol-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Noreugenin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.42% |
| Norkurarinol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NOTA-Pep-1L |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.60% |
| NP-1815-PX |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NP-1815-PX sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| NP3-146 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NP3-146 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.26% |
| NP3-253 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.78% |
| NP3-562 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.16% |
| NP3-742 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NPSR1 antagonist-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nrf2 activator-24 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NSC61610 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| NSC80734 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.08% |
| NT-0527 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| NTZ-24 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ocankitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Octyl decyldimethyl ammonium chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ODN 2216 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.57% |
| ODN M362 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.01% |
| ODN M362 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.02% |
| ODN TTAGGG |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
93.96% |
| Olcorolimus |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Oleanolic acid 28-O-β-D-glucopyranoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.42% |
| Oleracone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| OM-RCA-01 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Ompekimig |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Omtriptolide sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ON203 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Oncaspar |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| OPR-003 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Oroxylin A-7-O-glucuronide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| OSE-279 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| OSE-703 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| OSM-SMI-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ossirene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Oturkibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| Oxazolone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| P2X7-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| P2X7-IN-2 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| P2Y14R antagonist 4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| P53/TLR2 modulator-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| P60-L3-VHL |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Pacibekitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| Paeoniflorin-6′-O-benzene sulfonate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Palmitoyl hexapeptide-12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.17% |
| Palmitoyl Tetrapeptide-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.18% |
| Pam2CSK4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pam2CSK4 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.46% |
| Panaxytriol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Papiliocin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PARP14 inhibitor 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Patiromer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| Patrinoside aglucone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PBP10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.13% |
| PD 151746 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| PD-1/PD-L1-IN-54 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PD-1/PD-L1-IN-65 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDE/TRPA1/CHIT1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDE1-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDE1-IN-9 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDE3/4-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDE4-IN-18 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDE4-IN-22 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDE4-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDE4D inhibitor 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pegloxenatide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
90.00% |
| Pentadecane-d32 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.2% |
| Pentenocin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pentenocin B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Peonidin chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.70% |
| Pep-1 (uncapped) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| PF-04308515 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PF-06342674 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| PF-06817024 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PF-07245303 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PF-07899895 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.83% |
| PF-4878691 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.19% |
| PG-901 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.35% |
| PHI-501 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Phosphodiesterase-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/AKT-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ-IN-25 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ-IN-28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Picankibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.00% |
| PIM1-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.92% |
| Pinostrobin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Pinus pinaster bark extract |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.79% |
| Piperonylic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| pJAK2(1001-1013) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| PKC-theta inhibitor 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.45% |
| PNA5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PNRI-299 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pochonin D |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Poly (I:C):Kanamycin (1:1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
48.60% |
| Polyandric acid A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Polyinosinic-polycytidylic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| Polyinosinic-polycytidylic acid (GMP Like) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
90.5% |
| Pongamol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Ponumkibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.48% |
| Potassium 1H-indol-3-yl sulfate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| PPADS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PPARγ agonist 20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ppc-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PQA-18 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| Procyanidol B4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| PROTAC BTK Degrader-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.24% |
| PROTAC HDAC6 degrader 7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC HPK1 Degrader-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC HPK1 Degrader-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC HPK1 Degrader-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC IRAK4 degrader-13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.47% |
| PROTAC IRAK4 degrader-14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC JAK1/2 degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.47% |
| PROTAC PDE4 degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC SAMHD1 Degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Protectin D1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| Pseudoginsenoside RT4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.05% |
| PTPRO-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PY109 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.15% |
| Pyrazinib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pyrrothiogatain |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.61% |
| QL-1200186 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| QS-21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.93% |
| QS-21-Api |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| Quin-C7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| QX-004N |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| QX008N |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R-03201195 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R-348 choline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RAGE406R |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rat IL10 mRNA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RBN012811 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.79% |
| RCGD423 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| RDN2150 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RDN2150 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Recibokibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99% |
| REGN-10597 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| REGN-7257 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.34% |
| REGN6490 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| rel-(1S,2R)-Dihydro bupropion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| rel-(1S,2R)-Dihydro bupropion-d9 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| rel-Talmapimod hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| rel-(1S,2R)-Dihydro bupropion-d9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Relaxin H3 (human) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Relaxin H3 (human) TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rencofilstat |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
90.29% |
| Rentosertib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Resolvin D2 n-3 DPA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Resolvin D3 methyl ester |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revbekitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.18% |
| RG-7258 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rhamnose |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Rhamnose monohydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Riltovetbart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99% |
| RIPK1-IN-32 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RIPK1-IN-38 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RIPK1/RIPK3-PPI-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RIPK2-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RIPK3-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.98% |
| Ritlecitinib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| Ritlecitinib malonate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ritlecitinib tosylate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.65% |
| Ro26-4550 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ro26-4550 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RO2959 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.12% |
| RO2959 monohydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.03% |
| RO8323 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Roconkibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.15% |
| Rofleponide 21-palmitate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RORγ-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RORγt inverse agonist 35 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RORγt inverse agonist 37 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rosarin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Rosavin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| RP-54745 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| RPR-106541 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RS-0481 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RS17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| RTX-003 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ruvonoflast |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.29% |
| RVG |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| S217879 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| S7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.10% |
| Sabialimon P |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Santamarine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.85% |
| Sapelizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.31% |
| Sappanone A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Saquinavir-13C6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SAR444200 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SB 203580 sulfone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.25% |
| SB-273005 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| SC144 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.48% |
| SC144 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.98% |
| SCH-900117 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SCH708980 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schisantherin B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.75% |
| SCR-1481B1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| SDZ 224-015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.05% |
| Sec61-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.22% |
| Secukinumab (Anti-Human IL-17A) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.31% |
| sEH inhibitor-19 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| sEH-IN-21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| sEH-IN-23 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| sEH-IN-24 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| sEH/AChE-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Seladelpar (lysine dihydrate) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| Selnoflast |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.46% |
| Selnoflast calcium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Selnoflast monopotassium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Selnoflast potassium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Semapimod |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Semapimod tetrahydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.18% |
| Serrumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SGNLTKYWKKIWKPGIKKWIK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shegansu B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SHIP1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shizukaol B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96% |
| SHP1-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SHP2-IN-45 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SHR-1703 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SI-W052 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| SIK2-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.06% |
| Silydianin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| Simepdekinra |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.05% |
| Simlukafusp alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.90% |
| SIN 14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SIRT5-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SK48-E26 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SLP7111228 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SLP7111228 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| SM-17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.98% |
| SMA-12b |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SMAP-29 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.18% |
| SMI-10B13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| SMU-14a |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SMU-3k |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SMU-C409 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SMU-L11-R |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SMU-Z1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Smurf1-IN-A01 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| SMW139 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SNX281 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.96% |
| Sodium metatungstate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
93.4% |
| Solaprubart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.59% |
| Solrikitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.28% |
| SP-alkyne |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SP4206 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.97% |
| SPC-alkyne |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sphingomab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.91% |
| SQ 29548 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| SR12343 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| ST2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.05% |
| STAT1/3-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| STAT3-IN-46 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| STAT6-IN-12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| STAT6-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.53% |
| STAT6-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.11% |
| Stigmasta-3,5-dien-7-one |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| STING agonist-45 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.10% |
| STING agonist-50 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| STING-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.65% |
| STING-IN-13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| STING-IN-15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.04% |
| STING-IN-16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| STING-IN-18 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Strictosamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| SU5201 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.45% |
| Suc-YVAD-pNA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sugiol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Sunakiment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Surovatamig |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| t9,t11,c15-CLNA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tabirafusp alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.08% |
| TAK-603 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Talaromyketide B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tanimilast |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| TAT-327 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TAT-N15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TAT-N24 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TAVO101 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Taxamairin B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TBK1 degrader-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TBPH |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| TCR-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TCR-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tebentafusp |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Tectorigenin sodium sulfonate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Temtokibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| Teneligliptin hydrobromide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Tepilukimig |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.57% |
| Tepoditamab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99% |
| TFEB Decoy ODN sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
90.24% |
| Theasinensin C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Theophylline L-lysine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| THR-123 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| THR-123 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tilnoprofenic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TKP-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TL-895 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| TL8-506 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| TL8-506 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TLR4L 10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TLR7 agonist 8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TLR7 antagonist-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TLR7/8 agonist 13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TLR7/8 agonist 14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TLR7/8 agonist 6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.93% |
| TLR7/8 antagonist 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TLR9 antagonist 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TLR9 antagonist 1 diformate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TLR9 antagonist 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TMI-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.57% |
| TNF-α-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α-IN-19 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α/IL-1β-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α/IL-1β/IL-6-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNP-ATP triethylammonium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.7% |
| Tolododekin alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tomentosin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.95% |
| TPP-9476 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TQC2938 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TQH-2722 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TRC4186 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Trehalose-6,6'-dibehenate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| TREM-1 inhibitory peptide GF9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| Tributyrin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Tricarbonyldichlororuthenium(II) dimer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| TriDAP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TriDAP dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.65% |
| Trigraecum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Triptoquinone A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Triptoquinone B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Troponin-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TRPM8 antagonist 4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TRPV1 antagonist 10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.54% |
| Truncated ADR58 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tryptanthrin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| TSLP modulator-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| TSLP-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| Tubulin polymerization-IN-90 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tucotuzumab celmoleukin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.797% |
| Turenkibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.12% |
| Tyk2-IN-18-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tyk2-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.58% |
| Tyrphostin A1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.96% |
| UF010 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| UM-203 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| UM-242 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| UM-259 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Umckalin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Undecane |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| Undecane-d24 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| UR-1505 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| URAT1-IN-16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| VA06 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| VAK-694 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Valencene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
80.24% |
| Vamikibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Varokibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.69% |
| Vaxfectin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| VB-85247 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| VDJ001 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| VEGFR-2-IN-40 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Veledimex |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.77% |
| Veledimex (S enantiomer) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.17% |
| Veledimex racemate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Velvakiment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vemircopan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.61% |
| Verekitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.00% |
| VGX-1027 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| Vidofludimus |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.14% |
| Vidofludimus hemicalcium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vilamakitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.45% |
| Vimekofusp |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| VISTA-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vitamin K2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vitedoamine A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vitexin-4''-O-glucoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Vixarelimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.90% |
| VJDT |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| VO-OHPic |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vorbipiprant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.89% |
| VRT-18858 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vunakizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| VVD-118313 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.47% |
| WEHI-P8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Withaphysalin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| Wnt/β-catenin-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.34% |
| WWL229 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| Xanthine oxidase-IN-21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| XAT-14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Xelafaslatide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| XKH001 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| XmAb-662 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| XY-52 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Y 25510 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Y-320 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.03% |
| Y11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.34% |
| Y13g |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Y13g dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Yangambin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.27% |
| YM-90709 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| YM-I-26 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| YQ128 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| YSY01A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| YVAD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| YVAD-CHO TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.48% |
| Z-Ala-Ala-Asp-CMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.08% |
| Z169667518 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Zagociguat |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.09% |
| Zemlikafusp alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ZL-1211 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ZM734 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Zumilokibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.70% |
| α-Galactosylceramide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.85% |
| α-MSH (11-13) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| α-MSH (11-13) acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.31% |
| α7 nAchR-JAK2-STAT3 agonist 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.51% |
| β-Interleukin II (44-56) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Beta-Sitosterol (purity>98%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Gamma-glutamylcysteine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.53% |
| Gamma-glutamylcysteine TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.68% |
| Gypenoside A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Magnesium sulfate heptahydrate, meets analytical specification of Ph. Eur. BP USP FCC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Magnesium sulfate heptahydrate, United States Pharmacopeia (USP) Reference Standard |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Bivalirudin TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Tris(2-chloroethyl) phosphate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.07% |
| Tris(2-chloroethyl)phosphate-d12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.15% |
| Propacetamol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.02% |
| Probenecid sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.37% |
| Pretilachlor |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.25% |
| Sericin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0% |
| Rademikibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.13% |
| Levilimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.52% |
| Lupeol acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Theophylline sodium acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lactulose |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Lactose |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| N,N-Diethylacetamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dihydrosanguinarine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Diallyl Trisulfide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Coriolus Versicolor Extract |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Iminostilbene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| Geniposidic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.87% |
| Armillarisin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Ginsenoside Rc |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Ginsenoside Rh1 (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ginsenoside Rh1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.72% |
| Talmapimod |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.68% |
| Talmapimod hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tacalcitol monohydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Tacalcitol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| Eblasakimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Irsogladine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Ixekizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| Inolimomab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.78% |
| Firsekibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.387% |
| Spesolimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.10% |
| Epinastine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Epinastine (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95% |
| Ebdarokimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.36% |
| Enokizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| Clazakizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Crebanine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Grossamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Rabbit Fibrinogen |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Perfluorohexane |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.2% |
| Perfluoropentanoic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Gaultherin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| Keliximab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.23% |
| Rilonacept |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥95.0% |
| Nootkatone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Pivekimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.19% |
| Perfluorodecanoic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Nonadecanoic acid-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1-Tetradecanol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| 1-Tetradecanol-d7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Carebastine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| Camidanlumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| Cavidine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Canakinumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.84% |
| Urabrelimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.487% |
| Protosappanin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Deacetylasperulosidic Acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| Dehydrocostus Lactone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Demethylwedelolactone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Desoximetasone-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deapi-platycodin D3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.86% |
| Bicyclol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Disulfiram |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Diacerein (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| Diacerein-d6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Diacerein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.64% |
| Elaidic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Guselkumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| (S)-(+)-Carvone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.26% |
| Siltuximab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Stapokibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.37% |
| Gevokizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.12% |
| Mycophenolate Mofetil-d4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Mycophenolate Mofetil |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Imidazolidinyl urea |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Thiabendazole |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| (±)-Stylopine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Pseudolaric Acid B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.67% |
| Tubeimoside III |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Tubeimoside I |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Desoximetasone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.31% |
| Dexamethasone phosphate disodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Kukoamine A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Perakizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Talacotuzumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.82% |
| Remtolumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.24% |
| Chitoheptaose |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chitohexaose hexahydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| Karacoline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.58% |
| Fletikumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.24% |
| Fusidic acid sodium salt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| Ceftiofur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Ceftiofur hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.43% |
| Ceftiofur sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.02% |
| Ceftiofur-d3 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cefditoren |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.14% |
| Cefonicid sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| Nemolizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| Ordesekimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.08% |
| Oxelumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.31% |
| Olokizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.54% |
| Omeprazole |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Omeprazole sulfone (methoxy-d3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| Omeprazole-d6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Omeprazole sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.10% |
| Omeprazole-d3 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Omeprazole magnesium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Omeprazole-13C,d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.00% |
| Omeprazole-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.99% |
| Omeprazole-d3-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.09% |
| Omalizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.7% |
| Amdokitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.696% |
| Anrukinzumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.64% |
| Amcinonide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.11% |
| Microhelenin C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.55% |
| Berberrubine chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.28% |
| Ustekinumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Netakimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Nidanilimab (Nadunolimab) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| House Dust Mite Extract, from D.farinae |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hawthorn Extract |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cornuside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Basiliximab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Parishin C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.24% |
| Balsalazide-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balsalazide-d4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Balsalazide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.65% |
| Balsalazide disodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balsalazide sodium hydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.30% |
| Brodalumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.18% |
| Briakinumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Brazikumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.408% |
| Mitraphylline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| Dovanvetmab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dupilumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.2% |
| Conbercept |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.42% |
| Isoforskolin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Isoquinoline-15N |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Isosteviol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Isoastragaloside I |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| Cardenolide B-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Depemokimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.24% |
| Golimumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Gomisin D |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.56% |
| Tomaralimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.42% |
| Tocilizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.47% |
| Torudokimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99% |
| Tozorakimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.82% |
| Neochlorogenic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Neomangiferin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Omtriptolide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.02% |
| Prezalumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| Siaresinolic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Triamcinolone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Tralokinumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.12% |
| Tirnovetmab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Tibulizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.86% |
| Tildrakizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.46% |
| Tilrekimig |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.00% |
| Epimedin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.43% |
| 7,3',4'-Tri-O-methylluteolin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.20% |
| Calceolarioside B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| Periplogenin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| Periplogenin (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lebrikizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Gerilimzumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.19% |
| Subtilisin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Diethylcarbamazine citrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.01% |
| Pectolinarin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Saikosaponin B1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.42% |
| Tamarixetin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.80% |
| Roburic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Gliquidone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Eucalyptol-d6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Eucalyptol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Mulberroside A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Platycodin D2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Platycodin D3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.91% |
| (+)-Medioresinol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.13% |
| Ethyl palmitate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.09% |
| Phytohemagglutinin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
80.0% |
| Arecaidine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| Hesperetin 7-O-glucoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.38% |
| Pentadecane |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.88% |
| Pentadecane (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| Bivalirudin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Bimekizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| Flurbiprofen axetil |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| Flumethasone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Hydrocortisone hemisuccinate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Teneligliptin hydrobromide hydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Sodium chloride, United States Pharmacopeia (USP) Reference Standard |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sodium chloride, for molecular biology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Sodium chloride, for cell culture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Clofazimine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Lornoxicam |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| Kaolin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tabersonine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.02% |
| Tabersonine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.55% |
| Vopikitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.32% |
| Vobarilizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Sarilumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| Saquinavir-d9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Saquinavir |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Saquinavir mesylate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| Serratiopeptidase |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Telikibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.505% |
| Eupafolin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| Alisol F |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Ziltivekimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.75% |
| Lokivetmab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Lobeglitazone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.18% |
| Deltamethrin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Lysozyme |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| Lysophosphatidylcholines |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Breviscapine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.13% |
| Ganoderma Lucidum/Reishi Extract |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
41.20% |
| Bovine Endothelial cell growth supplement,suitable for cell culture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Taurohyodeoxycholic acid-d4 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Taurohyodeoxycholic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| Taurohyodeoxycholic acid sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Vitexin-2"-O-rhamnoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.78% |
| Vitexin-2"-O-rhamnoside (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tezepelumab (anti-TSLP) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Regaloside B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Hyaluronic acid (Mw:1000-2000Da) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reslizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.4% |
| Resatorvid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.31% |
| Risankizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.37% |
| Glycochenodeoxycholic acid sodium salt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.51% |
| Kansuinine A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Kansuinine B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| Mannan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.4% |
| Glycochenodeoxycholic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| JTE-607 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.64% |
| Methylthiouracil |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Suplatast (Tosilate) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| Cendakimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Beauvericin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Astringin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.97% |
| Interleukin (IL)-6 Receptor |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.21% |
| Praeruptorin E |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.18% |
| Kaempferol-3-O-glucorhamnoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| Saponarin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Saponarin (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ajugol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| Epinastine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Epinastine hydrochloride (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| Mycophenolate Mofetil-d4 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mycophenolate mofetil hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.17% |
| Naphazoline hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.38% |
| Phellodendrine chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| Nifuratel |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Naphazoline nitrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.12% |
| Sodium thiosulfate (99%, water≤1.0%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Sodium thiosulfate (98%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.30% |
| Sodium thiocyanate, GR, 99% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.14% |
| Potassium 1H-indol-3-yl sulfate-d4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Chondroitin sulfate (from chicken) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| Magnesium sulfate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.03% |
| Magnesium sulfate, for cell culture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| Diethyl phosphate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.08% |
| Fosfenopril |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Fosfenopril-d7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Terminolic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Isoprothiolane |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Araloside A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Chikusetsusaponin IVa methyl ester |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mirikizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Sonelokimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Corynoline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.84% |
| Fibrinogen (Bovine) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gynostemma Extract |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Roquinimex |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| Rohitukine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mogroside III-E |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| Grosvenorine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| Romurtide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mepolizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.4% |
| Phytolacca americana Lectin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hydroxypropyl Cellulose |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hidrosmin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.34% |
| 1,2,4-Trimethoxybenzene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Madecassic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Madecassic acid (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Desmosterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| Sesamoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Carminic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.19% |
| Lipoxin A4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Lipoxin A4-d5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lipoteichoic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ATP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| ATP-13C10,15N5,d14 (dilithium) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Suciraslimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.42% |
| (E)-Methyl 4-coumarate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| (E)-Methyl 4-coumarate (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Etokimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| Ivuxolimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Astegolimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| Avizakimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| Sesame Oil |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.2% |
| Sinapaldehyde |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| Lusvertikimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| Aloin (mixture of A&B) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| Aloin (mixture of A&B) (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fluorene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.07% |
| Fluorene-d8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Graveoline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Atractyloside A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.11% |
| Secukinumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.9% |
| Romilkimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.01% |
| Picfeltarraenin IA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.65% |
| Benzbromarone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Benzoylmesaconine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.56% |
| Benzoylpaeoniflorin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.47% |
| Inclisiran |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.96% |
| Inclisiran sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.08% |
| Stem bromelain |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Poricoic acid B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.60% |
| Skimmin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| Theophylline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Theophylline (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Theophylline-13C2,d6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Theophylline-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Theophylline monohydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Theophylline (sodium glycinate) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Orientin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Muromonab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.74% |
| Lecankitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| Ligufalimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.81% |
| Naphazoline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Terpinolene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Satralizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Gluconate Calcium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Gluconate sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
| Gluconate-1-13C sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Gluconate-d6 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Taraxasterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| Tribuloside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.95% |
| Bakkenolide A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Bufothionine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Doxorubicinone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.29% |
| Cetrelimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Tucotuzumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99% |
| Edpetiline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Sirukumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.83% |
| Raspberry ketone glucoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| Allura Red AC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| Nosantine racemate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sitostanol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| Peimine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Bermekimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.68% |
| Benralizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95% |
| Xeligekimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Friedelin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| Coenzyme Q0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Daclizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Damulin B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ergosterol peroxide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.57% |
| Nadifloxacin (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| Nadifloxacin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Prednisone acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Eupalinolide C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dendronobiloside D |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rotundic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.41% |
| Continentalic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| Apilimod |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Apilimod mesylate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.58% |
| Cergutuzumab amunaleukin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.5% |
| Afasevikumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95% |
| Abrezekimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Raleukin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.4% |
| Artemisic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| Fezakinumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Linoleate sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Diosmetin-7-O-β-D-glucopyranoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| 7,8-Dimethoxycoumarin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.75% |
| Manidipine-d4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Manidipine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Loganin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Lutikizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.54% |
| Guanosine 5'-diphosphate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Guanosine 5'-diphosphate sodium, 96% (HPLC) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Muscone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Xanthomicrol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.68% |
| Aflatoxin G1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| Phellodendrine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Negletein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.55% |
| Sinigrin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Sinigrin hydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Hecogenin acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.57% |